Condition: B-cell Acute Lymphoblastic Leukemia · Sponsor: Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.
This description comes directly from the study's public registry record.
Kevin Curran, MD · 1-833-MSK-KIDS · currank@mskcc.org
Jaap Jan Boelens, MD, PhD · 1-833-MSK-KIDS
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center (Data Collection Only) | Cincinnati, Ohio, United States | Recruiting |
| Children's Hospital of Philadelphia (Data Collection Only) | Philadelphia, Pennsylvania, United States | Recruiting |
| Baylor College Medical Center (Data Collection Only) | Houston, Texas, United States | Not Yet Recruiting |
| Texas Children's Hospital (Data Collection) | Houston, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223021